𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis

✍ Scribed by Ronald J. Bernardi; Lisa Bomgaars; Elizabeth Fox; Frank M. Balis; Merrill J. Egorin; Theodore F. Lagattuta; Alberta Aikin; Patricia Whitcomb; Jamie Renbarger; Frank S. Lieberman; Stacey L. Berg; Susan M. Blaney

Book ID
105992755
Publisher
Springer
Year
2007
Tongue
English
Weight
335 KB
Volume
62
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

Phase I trial of weekly docetaxel and ge
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies
✍ Tarek Mekhail; Thomas E. Hutson; Paul Elson; G. Thomas Budd; Gordon Srkalovic; T πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 1 views

## Abstract ## BACKGROUND A Phase I study using weekly docetaxel and gemcitabine was conducted to investigate toxicity; to determine the maximum tolerated dose (MTD) of each agent; and, in a preliminary fashion, to determine the antitumor activity of the combination. ## METHODS Docetaxel and gem